Publications scientifiques sur le VIH
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.
2017
Growth Horm IGF Res.
Braun LR, Feldpausch MN, Czerwonka N, et al.
37:1-6.
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.
2017
PLoS One.
Clemmons DR, Miller S, Mamputu J-C, et al.
12(6):e0179538.
Efficacy and safety of ibalizumab (IBA) in a Phase 3 study of heavily treatment-experienced patients with multi-drug resistant (MDR) HIV-1 infection [abstract].
2016
Open Forum Infect Dis.
Lalezari J, Fessel J, Schrader S, et al.
3(suppl 1):LB-6. Proceedings of IDWeek, 2016.
Efficacy and safety of ibalizumab (IBA) in a Phase 3 study of heavily treatment-experienced patients with multi-drug resistant (MDR) HIV-1 infection.
2016
Lalezari J.
Oral presentation #LB-6 at: IDWeek; Oct 26-30, 2016; New Orleans, Louisiana, USA.
Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat.
2015
PLoS One.
Mangili A, Falutz J, Mamputu J-C, et al.
10(10):e0140358.